In August, the Insights Association tussled with more state and federal privacy legislation, laws and regulation; considered the implications of COVID-19-related mandates for employers; analyzed pending changes to the pharmaceutical industry’s restrictions on interactions with doctors; and opposed a potential federal tax on companies operating online. We’re also nearing the finish line in our campaign to fix the California law requiring a minimum wage for research subjects.
The insights industry scored important legislative victories in the last month for pharmaceutical MR in Pennsylvania, data security in Utah, and more COVID-19 small business loans and grants at the federal level and in California. At the same time, we’re staring down lots of problematic legislation, including a new comprehensive data privacy law in Virginia and a complex excise tax on data collection in New York. Meanwhile, advocacy continues on issues like: California A.B. 2257; worrisome legislation in Congress that would allow for the unionization of research subjects; limitations on coronavirus-related exposure liability; the census; and restrictions on exit polling.
The Pennsylvania Pharmaceutical Manufacturing Prohibited Gifts Act (H.B. 593) includes an amendment recommended by the Insights Association that would protect bona fide marketing research with health care professionals.
August is normally quiet in Washington, DC, but in keeping with the theme of 2020, this month has been more frenetic. While we beat back new taxes on the insights industry, the Insights Association has had to tangle with the demise of the U.S.-EU Privacy Shield for data transfer, further pandemic relief, some new threats to pharma MR, the finalization of CCPA, and an attempt to rush the 2020 Census that threatens the statistical viability of most marketing research and data analytics in the U.S.
Maine Finalizes Pharmaceutical Regulations, Clarifying the Legality of Research Respondent Incentives for Physicians
In finalizing Maine’s ban on pharmaceutical manufacturer gifts to health care practitioners, the Maine Board of Pharmacy responded to the Insights Association that it should not restrict respondent incentives for participation in bona fide marketing research.
Adverse event reporting, with which some pharmaceutical and medical device manufacturers require assistance from their marketing research and data analytics departments and partners/vendors, continues during the COVID-19 crisis.
The Insights Association has scored several policy victories in recent months – on Capitol Hill and in states across the U.S. Here are some of the highlights with content links for you and your team, all made possible by your membership.
A look back, counting down the Insights Association's top seven advocacy wins from the last decade that helped our marketing research and data analytics industry members create competitive advantage.
A (data) gathering storm? An update on legislation and regulation impacting the insights industry in 2019
Insights Association lobbyist Howard Fienberg provides a 2019 update on legislation and regulation impacting the marketing research and data analytics industry for Quirks magazine.